FDA
-
-
-
-
-
-
-
Idera Pharma (IDRA) Shares Positive Results from Investigator-Sponsored Trial in Melanoma Patients at Amsterdam UMC, Enrollment Stopped Early for Efficacy
-
-
-
-
-
-
-
Idera Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Idera Pharma (IDRA) Announces $5 Million in Further Proceeds from Private Placement of up to $20.7 Million
-
-
-
-
-
-
-
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
-
-
-
-
-
-
-
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
-
-
-
-
-
-
-
Idera Pharma (IDRA) Announces Update and Corporate Outlook for 2020
-
-
-
-
-
-
-
Idera Pharmaceuticals Announces Initiation of the ILLUMINATE-206 Trial Evaluating Tilsotolimod in Combination with Nivolumab and Ipilimumab for the Treatment of Solid Tumors
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

